Quetiapine: A Pharmacoeconomic Review of its Use in Bipolar Disorder

PharmacoEconomics

Volumn 30, Issue 7, 2012, Pages 611-631

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARIPIPRAZOLE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ASTHENIA; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPEPSIA; EXTERNAL VALIDITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEADACHE; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; INCREASED APPETITE; INSOMNIA; LETHARGY; LIFE EXPECTANCY; MAINTENANCE THERAPY; MEDICAID; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEUROLEPTIC MALIGNANT SYNDROME; NOSE CONGESTION; OBESITY; ONSET AGE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE; SYSTEMATIC REVIEW (TOPIC); TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DIBENZOTHIAZEPINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862206506     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11208500-000000000-00000     Document Type: Review

References (73)

1. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005 May 25; 293 (20):2528-30 (Pubitemid 40705735)
2. Michalak EE, Murray G, Young AH, et al. Burden of bipolar depression:impact of disorder and medications on quality of life. CNS Drugs 2008; 22 (5):389-406 (Pubitemid 351508123)
3. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun; 62 (6):593-602 (Pubitemid 40973434)
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC:American Psyciatric Association, 2000
5. Manning JS. Burden of illness in bipolar depression. Prim Care Companion J Clin Psych 2006; 7 (6):259-67 (Pubitemid 44371603)
6. Malhi GS, Adams D, Cahill CM, et al. The management of individuals with bipolar disorder: A review of the evidence and its integration into clinical practice. Drugs 2009 Oct 22; 69 (15):2063-101
7. Scott J, Colom F, Popova E, et al. Long-term mental health resource utilization and cost of care following group psychoeducation or unstructured group support for bipolar disorders: A cost-benefit analysis. J Clin Psychiatry 2009; 70 (3):378-86
8. National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care (NICE clinical guideline no. 38) [online]. Available from URL:http://publications.nice.org.uk/bipolar-disordercg38 [Accessed 2011 Dec 5]
9. Hirschfeld RMA. Guideline watch:practice guideline for the treatment of patients with bipolar disorder. 2nd ed. American Psychiatric Association [online]. Available from URL:http://psychiatryonline.org/content.aspx?bookid= 28& sectionid=1682557 [Accessed 2011 Dec 5]
10. Fleurence RL, Dixon JM, Revicki DA. Economics of atypical antipsychotics in bipolar disorder: A review of the literature. CNS Drugs 2006; 20 (7):591-9 (Pubitemid 43990535)
11. AstraZeneca. Seroquel-(quetiapine fumarate) tablets:US prescribing information [online]. Available from URL:http://www1.astrazeneca-us.com/pi/ Seroquel.pdf [Accessed 2011 Oct 3]
12. AstraZeneca. Seroquel XR-(quetiapine fumarate) extended- release tablets:US prescribing information [online]. Available from URL:http://www1. astrazeneca-us.com/pi/ seroquelxr.pdf [Accessed 2011 Oct 3]
13. AstraZeneca. Seroquel-(quetiapine) film-coated tablets:summary of product characteristics [online]. Available from URL:http://www.medicines.org.uk/emc/ medicine/2295 [Accessed 2011 Oct 3]
14. AstraZeneca. Seroquel-(quetiapine) prolonged-release tablets:summary of product characteristics [online]. Available from URL:http://www.medicines.org. uk/emc/medi cine/21175 [Accessed 2011 Oct 3]
15. Fajutrao L, Locklear J, Priaulx J, et al. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health 2009; 5:3
16. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord 2002 Dec; 4 (6):398-405 (Pubitemid 36041470)
17. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276 (4):293-9 (Pubitemid 26249533)
18. Hirschfeld RM, Vornik LA. Bipolar disorder:costs and comorbidity. Am J Manag Care 2005 Jun; 11 (3 Suppl.):S85-90
19. Frye MA, Calabrese JR, Reed ML, et al. Healthcare resource utilization in bipolar depression compared with unipolar depression:results of a United States populationbased study. CNS Spectr 2006 Sep; 11 (9):704-10 (Pubitemid 44449655)
20. Kasper S. Issues in the treatment of bipolar disorder. Eur Neuropsychopharmacol 2003 Aug; 13 Suppl. 2:S37-42 (Pubitemid 37083231)
21. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors:global burden of disease study. Lancet 1997 May 17; 349 (9063):1436-42 (Pubitemid 27212192)
22. Wyatt RJ, Henter I. An economic evaluation of manicdepressive illness:1991. Soc Psychiatry Psychiatr Epidemiol 1995 Aug; 30 (5):213-9
23. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002 Mar; 180:227-33
24. Hakkaart-van Roijen L, Hoeijenbos MB, Regeer EJ, et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand 2004 Nov; 110 (5):383-92 (Pubitemid 39424840)
25. Runge C, Grunze H. Annual costs of bipolar disorders in Germany [in German]. Nervenarzt 2004 Sep; 75 (9):896-903 (Pubitemid 39312515)
26. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: An estimate for new cases in 1998. Pharmacoeconomics 2001; 19 (5 Pt 1):483-95 (Pubitemid 32488750)
27. Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder:clinical and parity implications. Am J Psychiatry 2003 Jul; 160 (7):1286-90 (Pubitemid 41070945)
28. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999 Oct; 50 (10):1303-8 (Pubitemid 29468533)
29. Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: A retrospective, cross-sectional, descriptive analysis. Clin Ther 2002 Oct; 24 (10):1668-76 (Pubitemid 35351851)
30. Perlick D, Clarkin JF, Sirey J, et al. Burden experienced by care-givers of persons with bipolar affective disorder. Br J Psychiatry 1999 Jul; 175:56-62 (Pubitemid 29307856)
31. Chatterton ML, Ke X, Lewis BE, et al. Impact of bipolar disorder on the family:utilization and cost of health care resources. P T 2008 Jan; 33 (1):15-34
32. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008 Jan 17; 358 (3):252-60
33. Chiesa A, Chierzi F, De Ronchi D, et al. Quetiapine for bipolar depression: A systematic review and meta- Analysis. Int Clin Psychopharmacol 2012 Mar; 27 (2):76-90
34. Vieta E, Gunther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: A meta- Analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011 Sep; 14 (8):1029-49
35. Vieta E, Locklear J, Gunther O, et al. Treatment options for bipolar depression: A systematic review of randomized, controlled trials. J Clin Psychopharmacol 2010Oct; 30 (5):579-90
36. SanfordM, KeatingGM. Quetiapine: A review of its use in the management of bipolar depression. CNS Drugs. In press
37. Keating GM, Robinson DM. Quetiapine: A review of its use in the treatment of bipolar depression. Drugs 2007; 67 (7):1077-95 (Pubitemid 46744479)
38. Cristancho MA, Thase ME. The role of quetiapine extended release in the treatment of bipolar depression. Adv Ther 2010 Nov; 27 (11):774-84
39. Brahm NC, Gutierres SL, Carnahan RM. Quetiapine for acute mania in bipolar disorder. Am J Health Syst Pharm 2007 May 15; 64 (10):1045-53 (Pubitemid 46801536)
40. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta- Analysis. Lancet 2011 Oct 8; 378 (9799):1306-15
41. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005 Jan; 66 (1):111-21
42. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: A 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005 Oct; 15 (5):573-85 (Pubitemid 41219629)
43. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study. Bipolar Disord 2004 Jun; 6 (3):213-23 (Pubitemid 38702297)
44. Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005 Jul; 162 (7):1351-60 (Pubitemid 40905587)
45. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010 Feb; 71 (2):163-74
46. Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010 Feb 1; 121:106-15
47. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006 Dec; 26 (6):600-9 (Pubitemid 44772737)
48. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010 Feb; 71 (2):150-62
49. Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder:results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009 Apr; 166 (4):476-88
50. Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008 Aug; 109 (3):251-63
51. Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: A randomized controlled study). J Clin Psychiatry 2011 Nov; 72 (11):1452-64
52. Gianfrancesco F, Pesa J, Wang RH. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. J Manage Care Pharm 2005 Apr; 11 (3):220-30
53. Jing Y, Kim E, YouM, et al. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Econ 2009 Jun; 12 (2):104-13
54. Gianfrancesco F, Rajagopalan K, Goldberg JF, et al. Hospitalization risks in the treatment of bipolar disorder:comparison of antipsychotic medications. Bipolar Disord 2007 May; 9 (3):252-61 (Pubitemid 46547119)
55. Qiu Y, Christensen DB, Fu AZ, et al. Cost analysis in a Medicaid program for patients with bipolar disorder who initiated atypical antipsychotic monotherapy. Curr Med Res Opin 2009 Feb; 25 (2):351-61
56. Caro JJ, Huybrechts KF, Xenakis JG, et al. Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: An economic analysis of clinical trials. Curr Med Res Opin 2006 Nov; 22 (11):2233-42 (Pubitemid 44789988)
57. Klok RM, Al Hadithy AF, van Schayk NP, et al. Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder. Expert Rev 2007 Oct; 7 (5):459-67 (Pubitemid 350120040)
58. Fajutrao L, Paulsson B, Liu S, et al. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder:results of a Markov model analysis. Clin Ther 2009 Jun; 31 Pt 1:1456-68
59. Woodward TC, Tafesse E, Quon P, et al. Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder. J Med Econ 2009; 12 (4):259-68
60. Woodward TC, Tafesse E, Quon P, et al. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics 2010 Sep 1; 28 (9):751-64
61. Bridle C, Palmer S, Bagnall AM, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 2004 May; 8 (19):iii-v
62. Ekman M, Lindgren P, Miltenburger C, et al. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. Pharmacoeconomics 2012; 30 (6):513-30
63. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London:NICE, 2008 Jun [online]. Available from URL:http://www.nice. org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008. pdf [Accessed 2011 Apr 7]
64. Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value Health 2010; 13 (6):853-6
65. Jonsson B. Changing health environment: The challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4:5-10 (Pubitemid 40066088)
66. Eichler HG, Kong SX, Gerth WC, et al. Use of costeffectiveness analysis in health-care resource allocation decision-making:how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7 (5):518-28 (Pubitemid 39390832)
67. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009 Mar 17; 33 (2):199-204
68. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments:combining direct and indirect evidence. BMJ 2005 Oct 15; 331:897-900 (Pubitemid 41502718)
69. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991 May 9; 324 (19):1362-5
70. Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009 Feb 15; 66 (4):358-65
71. Gianfrancesco FD, Sajatovic M, Rajagopalan K, et al. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther 2008 Jul; 30 (7):1358-74
72. Hassan M, Madhavan SS, Kalsekar ID, et al. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann Pharmacother 2007 Nov; 41 (11):1812-8 (Pubitemid 350044343)
73. Gianfrancesco FD, Rajagopalan K, Sajatovic M, et al. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry 2006 Feb; 67 (2):222-32 (Pubitemid 43357468)